Effects of CLA Supplements on Body Weight and Fat Oxidation

This study has been completed.
Sponsor:
Information provided by:
University of Wisconsin, Madison
ClinicalTrials.gov Identifier:
NCT00204932
First received: September 12, 2005
Last updated: April 5, 2010
Last verified: April 2010

September 12, 2005
April 5, 2010
July 2004
January 2008   (final data collection date for primary outcome measure)
loss of body fat [ Time Frame: 6 months ] [ Designated as safety issue: No ]
Body fatness
loss of body fat
Complete list of historical versions of study NCT00204932 on ClinicalTrials.gov Archive Site
total fat oxidation [ Time Frame: 6 months ] [ Designated as safety issue: Yes ]
Blood chemistries and general well being
total fat oxidation
Not Provided
Not Provided
 
Effects of CLA Supplements on Body Weight and Fat Oxidation
Effects of CLA Supplements on Body Weight and Fat Oxidation

Conjugated linoleic acid (CLA) is form of fat found in dairy foods, beef and other natural sources. When given to small animals, decreases of body fat have been noted.. Although weight loss is the best treatment for overweight and obesity, it is difficult to maintain the loss in the long term. Because of this, treatment emphasis has turned to small weight losses obtained through non-restrictive diets and prevention of weight regain. This is a study to determine if 6 months of consumption a purified form of CLA will result in greater loss of body fat than control and to determine whether CLA consumption increases total fat oxidation, which would help explain why the weight loss occurs.

Not Provided
Interventional
Phase 2
Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Obesity
Drug: conjugated linoleic acid
  • Active Comparator: CLA
    Intervention: Drug: conjugated linoleic acid
  • Placebo Comparator: Placebo
    Intervention: Drug: conjugated linoleic acid
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
53
January 2008
January 2008   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • BMI 25-29.9 kg/m2
  • Absence of a weight change of greater than 3 kg in the previous 6 months

Exclusion Criteria:

  • Presence of a physical limitation to walking exercise
  • Current or recent (6 months) enrollment in a commercial or self-prescribed weight loss program
  • A history of metabolic disease-ie. renal, endocrine, hepatic or gastrointestinal disease that would impact the outcome of the study
  • A history of a psychiatric or eating disorders Ÿ Presence of metal implants that would interfere with body composition analysis
  • Fasting plasma cholesterol >300mg/dl or triglycerides above 500 mg/dl.
  • Abnormal EKG
Both
18 Years to 44 Years
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00204932
2004-0060
Yes
Dale A. Schoeller, University of Wisconsin-Madison
University of Wisconsin, Madison
Not Provided
Study Chair: Dale A Schoeller, PhD University of Wisconsin, Madison
Principal Investigator: Dale A Schoeller, PhD University of Wisconsin, Madison
University of Wisconsin, Madison
April 2010

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP